Developer docs
API playgroundTry for free, no card

Search company profiles

Izotropic

Full company profile

uuid0000uni

Namestring
Izotropic
Legal namestring
Izotropic Corporation
Websiteurl
izocorp.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Izotropic Corporation is a publicly traded medical device company (CSE: IZO, OTCQB: IZOZF, FSE: 1R3), founded in 2015 and headquartered in Surrey, British Columbia, with engineering operations in Sacramento, California. The company is commercializing the IzoView Breast CT Imaging System, a dedicated breast CT platform that produces true 3D volumetric images (approximately 500 high-resolution images per scan in 10 seconds, with reconstruction in 30 seconds) without breast compression. The underlying technology was developed at UC Davis Medical Center over approximately 20 years of clinical research, and Izotropic holds exclusive global licensing rights. The system is designed primarily for the approximately 50% of women with dense breast tissue (BI-RADS density categories C and D), where standard-of-care mammography and digital breast tomosynthesis have reduced sensitivity, and targets a U.S. eligible population of roughly 35.45 million women annually.

The platform's differentiating components include a proprietary self-supervised deep-learning reconstruction algorithm co-developed with Johns Hopkins University School of Medicine and protected as a trade secret, a patent-pending optical pre-scan system for personalized radiation dose, the only U.S. patent for computer-aided diagnosis with breast CT (planned as a post-market software upgrade), and a modular, self-shielded design that allows installation in standard rooms without leaded walls. Reported technical performance includes detection of lesions as small as 2 mm (vs. ~11 mm average on screening mammography) and spatial resolution 100x greater than MRI, at a target unit price of $500,000 — well below competing breast CT systems ($1.2M–$1.5M) and MRI systems ($1M–$3M+). The device has not yet received U.S. FDA approval or CE Mark; Izotropic is pursuing a Pre-Market Approval pathway and has achieved FDA alignment on its clinical study design following a pre-submission meeting in March 2025, with a pivotal clinical study of approximately 2.5 years and $3.5M planned.

Izotropic's business model is pre-commercial and depends on hardware sales as the primary future revenue stream, supplemented by post-market software upgrades tied to 14 identified future Indications for Use and by sublicensing/distribution economics through the Izotropic Africa joint venture (40% interest, covering 38 African countries and 6 GCC nations). The company plans an EU-first commercial launch, followed by the United States, with go-to-market centered on direct enterprise sales to hospitals, breast centers, and imaging clinics, and an initial wave of clinical-study-site sales at discounted rates. To date, operating capital has been raised through a CAD $2M unsecured loan (April 2022, balance of CAD $2.675M as of March 2025) and a series of small non-brokered private placements totaling roughly CAD $1.13M between February 2025 and February 2026; no commercial revenue has been recorded.

Short descriptiontext

Izotropic Corporation is a publicly traded medical device company developing the IzoView Breast CT Imaging System, a dedicated 3D breast CT platform targeting the ~50% of women with dense breast tissue where mammography underperforms. The device is pre-commercial, pending FDA Pre-Market Approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast CT imaging, medical imaging devices, computed tomography systems, cancer screening equipment, diagnostic imaging hardware
Industry2 codes
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
  • Surgical & Medical Instruments & Apparatus3841
Product category
Breast Imaging Diagnostic Equipment
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1IzoView Breast CT Device Sales
TypeHardware Sales
Description

Sale of IzoView Breast CT Imaging System as the primary revenue stream. Target sales price of USD $500,000 per unit, significantly below competing breast CT systems ($1.2M-$1.5M) and MRI systems ($1M-$3M+). Initial sales will focus on clinical study sites at discounted rates, expanding to hospitals, medical facilities, and imaging clinics globally.

izocorp.com
2Software Upgrades and Expanded Indications
TypeLicensing Royalties
Description

Post-approval software upgrades enabling additional Indications for Use (14 identified across screening, diagnosis, monitoring, planning, and personalized medicine). Early adopters can increase clinical utility without replacing core system, creating recurring revenue model and upgrade incentives.

izocorp.com
3Sublicensing and Distribution Fees (Izotropic Africa)
TypeLicensing Royalties
Description

Under the Letter Agreement, Izotropic holds 40% fully diluted interest in Izotropic Africa joint venture. Sub-licensing rights enable commercialization in global business sectors in exchange for sales revenues, distribution fees, and/or pay-per-use fees on licensed products across Africa and GCC countries.

stocktitan.net
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details3 tiers
1IzoView Breast CT Imaging System - Target Price
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Target sales price of USD $500,000 per unit. This represents 40-67% lower cost than competing breast CT systems on the market.

izocorp.com
2Clinical Study Site Pricing
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Initial sales to clinical study sites at discounted rates (customary practice).

izocorp.com
3Exam/Scan Pricing - Target
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Target exam cost of $250-$500 per scan. Compare to MRI exam costs of $400-$6,000+ and ABUS at $400-$500.

izocorp.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Izotropic Africa
Description

Regional operations hub based in Casablanca, Morocco, operating across 38 African countries and all six GCC nations for licensing, marketing, distribution, and evaluation of manufacturing of IzoView Breast CT products

stocktitan.net
Core offering1 text field

Izotropic develops and intends to commercialize the IzoView Breast CT Imaging System, a dedicated breast computed tomography platform engineered for breast cancer screening in women with dense breast tissue. The device delivers true 3D, 360-degree volumetric breast imaging without compression, supported by a proprietary AI-based machine-learning reconstruction algorithm developed with Johns Hopkins University. The system is being positioned for adjunctive screening to digital breast tomosynthesis (DBT) at a target sales price of $500,000 per unit, with planned software-enabled expansion across 14 potential indications for use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Detection of 2mm lesions vs 11mm average mammography detection, enabling approximately 1.25 years earlier cancer detection
+6 more records
Product overview1 text field

Izotropic Corporation offers the IzoView Breast CT Imaging System as its flagship medical device product, a dedicated breast CT platform purpose-built for the 50% of women with dense breast tissue where traditional mammography and tomosynthesis often fail to detect cancers. IzoView combines true 3D imaging without breast compression, proprietary AI-powered image reconstruction, and a modular engineering design at a target price of $500,000—significantly below competing breast CT systems ($1.2M-$1.5M). The platform is designed to bridge the gap between digital breast tomosynthesis and MRI, with planned expansion to 14 indications for use and computer-aided diagnosis (CADx) software capabilities. The company is pursuing U.S. FDA Pre-Market Approval (PMA) and European CE Mark regulatory pathways, with the device not yet approved for commercial sale.

Product and service1 record
1IzoView Breast CT Imaging System
CategoryMedical Imaging Equipment / Breast CT Hardware
Description

A dedicated breast CT imaging system designed for breast cancer screening adjunctive to digital breast tomosynthesis (DBT) in women with dense breast tissue. Provides true 3D volumetric imaging without breast compression, 100x greater spatial resolution than MRI, a proprietary AI reconstruction algorithm, and a patent-pending personalized radiation dose system. Target sales price of $500,000 per unit with 14 potential future indications for use deliverable through software upgrades. Currently pursuing FDA PMA and CE Mark.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Mohammed VI Foundation for Science & Health (FM6SS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Partnership discussions focused on clinical research, regulatory advancement, and localized manufacturing of IzoView Breast CT Imaging System in Morocco. Under discussions, IzoView device valued at USD $500,000 would be placed at leading Moroccan hospital at no cost for clinical evaluation. Parties aim to finalize formal agreement by April 30, 2026 (extended to June 30, 2026). FM6SS is public utility institution under patronage of King Mohammed VI.

newsfilecorp.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Letter Agreement signed February 2026 to establish Izotropic Africa joint venture entity based in Casablanca, Morocco. Business group holds 60% fully diluted interest; Izotropic retains 40%. Entity will license, market, distribute, and evaluate manufacturing of IzoView Breast CT products across Africa and GCC. Izotropic's 40% share of first-year startup budget is approximately USD $120,000. Distribution planned across 38 African countries and 6 GCC nations.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-09-19
Description

Arm's-length marketing firm engaged for 12-month term (ending September 2026) at CAD $60,000. Provides investor awareness and digital marketing services including social media advertising, communications strategies, brand development, and coordination with advertising partners.

4Departures Capital Inc.
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-09-19
Description

Service agreement for strategic consulting, investor communications, digital media production, and related services. One-year term expiring September 2026 at CAD $25,000. Arm's-length party with no equity interest in the company.

izocorp.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive global licensing agreement to breast CT technology developed at UC Davis Medical Center. Covers all patents, patent applications, and technology for screening, diagnostic, and therapeutic use in humans. Includes sublicensing rights for global commercialization. Amended June 2025 with alignment on regulatory milestones. Diligence obligation fee of USD $85K due November 2025.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration with Johns Hopkins University School of Medicine to develop proprietary AI-based machine-learning reconstruction algorithm. Algorithm trained on 15 years of specialized breast CT data and protected as trade secret by Izotropic.

7JG Global Communications (James Gagnon)
Strategic tierMinorTypeGTM or Marketing Partner
Description

International Communications Consultant engaged for 6-month term at $6,000/month. James Gagnon brings 20+ years experience in international finance and investor relations with multilingual capabilities. Leads proactive outbound investor communications and global outreach focusing on Asia and Europe markets.

izocorp.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Hologic is the dominant incumbent in breast imaging via its 3D mammography / Genius DBT platform (Selenia Dimensions, 3Dimensions) and serves the same hospital and breast-center customers IzoView targets. Comparable as the entrenched workflow IzoView must displace or supplement.

TypeEmerging player
Description

Lunit develops AI software (Lunit INSIGHT) for mammography and DBT breast cancer detection, with FDA-cleared products. Comparable as a software-AI peer in breast imaging whose AI-vs-AI narrative parallels Izotropic's AI reconstruction and planned CADx positioning.

TypeBroad incumbent
Description

Fujifilm offers digital mammography systems and broader imaging/PACS infrastructure to hospitals and imaging centers. Comparable as a multi-modality incumbent competing for breast imaging capital budgets and downstream IT integration.

TypeEmerging player
Description

Volpara provides breast density assessment and AI-based imaging analytics software integrated with mammography workflows. Comparable as an emerging software peer addressing the dense-breast population that IzoView's primary indication targets, although Volpara is software-only rather than capital equipment.

TypeBroad incumbent
Description

Canon Medical supplies digital mammography systems and a broader imaging portfolio to the same hospital and outpatient imaging customers. Comparable as a multi-modality incumbent in breast imaging capital equipment.

TypeBroad incumbent
Description

Siemens provides mammography (MAMMOMAT), MRI, and AI imaging solutions for the same radiology departments and breast centers IzoView targets. Comparable as an established, multi-modality competitor with strong European footprint aligned to Izotropic's planned EU-first launch.

TypeDirect peer
Description

Koning is the most directly comparable peer — a commercial-stage developer of dedicated cone-beam breast CT systems (Koning KBCT) that compete head-to-head with IzoView in the dedicated breast CT category. Both target the dense-breast screening indication and the same hospital/imaging-center buyer.

TypeBroad incumbent
Description

Philips offers mammography, ultrasound, MRI, and AI-enabled diagnostic imaging for similar hospital and breast-center buyers. Comparable as a broad incumbent competing for the same capital equipment budget and radiology workflow share.

TypeBroad incumbent
Description

GE offers mammography (Senographe Pristina), MRI, and contrast-enhanced imaging across the same hospital buyers as Izotropic. It is a broad incumbent whose installed base and service network set the competitive benchmark for breast imaging procurement.

TypeEmerging player
Description

iCAD provides AI-based computer-aided detection (ProFound AI) for breast cancer screening on mammography and DBT. Comparable because it overlaps with Izotropic's planned CADx module and targets the same radiologist end-user with AI decision support. Izotropic's former regulatory consultant John DeLucia was previously VP at iCAD.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Izotropic

Breast Imaging Diagnostic Equipmentizocorp.com

Izotropic Corporation is a publicly traded medical device company developing the IzoView Breast CT Imaging System, a dedicated 3D breast CT platform targeting the ~50% of women with dense breast tissue where mammography underperforms. The device is pre-commercial, pending FDA Pre-Market Approval.

What Izotropic does

Izotropic Corporation is a publicly traded medical device company (CSE: IZO, OTCQB: IZOZF, FSE: 1R3), founded in 2015 and headquartered in Surrey, British Columbia, with engineering operations in Sacramento, California. The company is commercializing the IzoView Breast CT Imaging System, a dedicated breast CT platform that produces true 3D volumetric images (approximately 500 high-resolution images per scan in 10 seconds, with reconstruction in 30 seconds) without breast compression. The underlying technology was developed at UC Davis Medical Center over approximately 20 years of clinical research, and Izotropic holds exclusive global licensing rights. The system is designed primarily for the approximately 50% of women with dense breast tissue (BI-RADS density categories C and D), where standard-of-care mammography and digital breast tomosynthesis have reduced sensitivity, and targets a U.S. eligible population of roughly 35.45 million women annually.

The platform's differentiating components include a proprietary self-supervised deep-learning reconstruction algorithm co-developed with Johns Hopkins University School of Medicine and protected as a trade secret, a patent-pending optical pre-scan system for personalized radiation dose, the only U.S. patent for computer-aided diagnosis with breast CT (planned as a post-market software upgrade), and a modular, self-shielded design that allows installation in standard rooms without leaded walls. Reported technical performance includes detection of lesions as small as 2 mm (vs. ~11 mm average on screening mammography) and spatial resolution 100x greater than MRI, at a target unit price of $500,000 — well below competing breast CT systems ($1.2M–$1.5M) and MRI systems ($1M–$3M+). The device has not yet received U.S. FDA approval or CE Mark; Izotropic is pursuing a Pre-Market Approval pathway and has achieved FDA alignment on its clinical study design following a pre-submission meeting in March 2025, with a pivotal clinical study of approximately 2.5 years and $3.5M planned.

Izotropic's business model is pre-commercial and depends on hardware sales as the primary future revenue stream, supplemented by post-market software upgrades tied to 14 identified future Indications for Use and by sublicensing/distribution economics through the Izotropic Africa joint venture (40% interest, covering 38 African countries and 6 GCC nations). The company plans an EU-first commercial launch, followed by the United States, with go-to-market centered on direct enterprise sales to hospitals, breast centers, and imaging clinics, and an initial wave of clinical-study-site sales at discounted rates. To date, operating capital has been raised through a CAD $2M unsecured loan (April 2022, balance of CAD $2.675M as of March 2025) and a series of small non-brokered private placements totaling roughly CAD $1.13M between February 2025 and February 2026; no commercial revenue has been recorded.

Izotropic firmographics

Firmographics
Name
Izotropic
Legal name
Izotropic Corporation
Website
https://izocorp.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Izotropic Corporation is a publicly traded medical device company developing the IzoView Breast CT Imaging System, a dedicated 3D breast CT platform targeting the ~50% of women with dense breast tissue where mammography underperforms. The device is pre-commercial, pending FDA Pre-Market Approval.
Ownership category
akta.pro rank

Izotropic industry classification

Industry
Product category
Breast Imaging Diagnostic Equipment
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Breast CT imaging
  • Medical imaging devices
  • Computed tomography systems
  • Cancer screening equipment
  • Diagnostic imaging hardware

Where Izotropic is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

Izotropic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. IzoView Breast CT Device Sales: Sale of IzoView Breast CT Imaging System as the primary revenue stream. Target sales price of USD $500,000 per unit, significantly below competing breast CT systems ($1.2M-$1.5M) and MRI systems ($1M-$3M+). Initial sales will focus on clinical study sites at discounted rates, expanding to hospitals, medical facilities, and imaging clinics globally.
  2. Software Upgrades and Expanded Indications: Post-approval software upgrades enabling additional Indications for Use (14 identified across screening, diagnosis, monitoring, planning, and personalized medicine). Early adopters can increase clinical utility without replacing core system, creating recurring revenue model and upgrade incentives.
  3. Sublicensing and Distribution Fees (Izotropic Africa): Under the Letter Agreement, Izotropic holds 40% fully diluted interest in Izotropic Africa joint venture. Sub-licensing rights enable commercialization in global business sectors in exchange for sales revenues, distribution fees, and/or pay-per-use fees on licensed products across Africa and GCC countries.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractIzoView Breast CT Imaging System - Target Price
One time/ perpetual licenseOne time/ perpetual licenseClinical Study Site Pricing
Unit PricingPay-as-you-goExam/Scan Pricing - Target

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Izotropic product offering

Product offering

Core offering

Izotropic develops and intends to commercialize the IzoView Breast CT Imaging System, a dedicated breast computed tomography platform engineered for breast cancer screening in women with dense breast tissue. The device delivers true 3D, 360-degree volumetric breast imaging without compression, supported by a proprietary AI-based machine-learning reconstruction algorithm developed with Johns Hopkins University. The system is being positioned for adjunctive screening to digital breast tomosynthesis (DBT) at a target sales price of $500,000 per unit, with planned software-enabled expansion across 14 potential indications for use.

Product overview

Izotropic Corporation offers the IzoView Breast CT Imaging System as its flagship medical device product, a dedicated breast CT platform purpose-built for the 50% of women with dense breast tissue where traditional mammography and tomosynthesis often fail to detect cancers. IzoView combines true 3D imaging without breast compression, proprietary AI-powered image reconstruction, and a modular engineering design at a target price of $500,000—significantly below competing breast CT systems ($1.2M-$1.5M). The platform is designed to bridge the gap between digital breast tomosynthesis and MRI, with planned expansion to 14 indications for use and computer-aided diagnosis (CADx) software capabilities. The company is pursuing U.S. FDA Pre-Market Approval (PMA) and European CE Mark regulatory pathways, with the device not yet approved for commercial sale.

Differentiator

Problem solved

Functional benefit

Brands

  • Izotropic Africa: Regional operations hub based in Casablanca, Morocco, operating across 38 African countries and all six GCC nations for licensing, marketing, distribution, and evaluation of manufacturing of IzoView Breast CT products

Products and services

  • IzoView Breast CT Imaging System A dedicated breast CT imaging system designed for breast cancer screening adjunctive to digital breast tomosynthesis (DBT) in women with dense breast tissue. Provides true 3D volumetric imaging without breast compression, 100x greater spatial resolution than MRI, a proprietary AI reconstruction algorithm, and a patent-pending personalized radiation dose system. Target sales price of $500,000 per unit with 14 potential future indications for use deliverable through software upgrades. Currently pursuing FDA PMA and CE Mark.

Quantifiable outcome

  • Detection of 2mm lesions vs 11mm average mammography detection, enabling approximately 1.25 years earlier cancer detection
  • +6 more outcomes

Companies that use Izotropic

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Izotropic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Izotropic partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Mohammed VI Foundation for Science & Health (FM6SS)coreStrategic or Co-development Partner · 25 February 2026Partnership discussions focused on clinical research, regulatory advancement, and localized manufacturing of IzoView Breast CT Imaging System in Morocco. Under discussions, IzoView device valued at USD $500,000 would be placed at leading Moroccan hospital at no cost for clinical evaluation. Parties aim to finalize formal agreement by April 30, 2026 (extended to June 30, 2026). FM6SS is public utility institution under patronage of King Mohammed VI.
  • Business Group (Izotropic Africa Joint Venture Partner)coreStrategic or Co-development Partner · 18 February 2026Letter Agreement signed February 2026 to establish Izotropic Africa joint venture entity based in Casablanca, Morocco. Business group holds 60% fully diluted interest; Izotropic retains 40%. Entity will license, market, distribute, and evaluate manufacturing of IzoView Breast CT products across Africa and GCC. Izotropic's 40% share of first-year startup budget is approximately USD $120,000. Distribution planned across 38 African countries and 6 GCC nations.
  • Evolux Capital (1822053 Alberta Ltd.)minorGTM or Marketing Partner · 19 September 2025Arm's-length marketing firm engaged for 12-month term (ending September 2026) at CAD $60,000. Provides investor awareness and digital marketing services including social media advertising, communications strategies, brand development, and coordination with advertising partners.
  • Departures Capital Inc.minorGTM or Marketing Partner · 19 September 2025Service agreement for strategic consulting, investor communications, digital media production, and related services. One-year term expiring September 2026 at CAD $25,000. Arm's-length party with no equity interest in the company.
  • University of California, Davis (UC Davis)coreOEM/ Whitelabel/ Licensing PartnerExclusive global licensing agreement to breast CT technology developed at UC Davis Medical Center. Covers all patents, patent applications, and technology for screening, diagnostic, and therapeutic use in humans. Includes sublicensing rights for global commercialization. Amended June 2025 with alignment on regulatory milestones. Diligence obligation fee of USD $85K due November 2025.
  • Johns Hopkins University School of MedicinecoreTechnology or IntegrationCollaboration with Johns Hopkins University School of Medicine to develop proprietary AI-based machine-learning reconstruction algorithm. Algorithm trained on 15 years of specialized breast CT data and protected as trade secret by Izotropic.
  • JG Global Communications (James Gagnon)minorGTM or Marketing PartnerInternational Communications Consultant engaged for 6-month term at $6,000/month. James Gagnon brings 20+ years experience in international finance and investor relations with multilingual capabilities. Leads proactive outbound investor communications and global outreach focusing on Asia and Europe markets.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Izotropic competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Hologic is the dominant incumbent in breast imaging via its 3D mammography / Genius DBT platform (Selenia Dimensions, 3Dimensions) and serves the same hospital and breast-center customers IzoView targets. Comparable as the entrenched workflow IzoView must displace or supplement.
  • Fujifilm Healthcare: Fujifilm offers digital mammography systems and broader imaging/PACS infrastructure to hospitals and imaging centers. Comparable as a multi-modality incumbent competing for breast imaging capital budgets and downstream IT integration.
  • Canon Medical Systems: Canon Medical supplies digital mammography systems and a broader imaging portfolio to the same hospital and outpatient imaging customers. Comparable as a multi-modality incumbent in breast imaging capital equipment.
  • Siemens Healthineers: Siemens provides mammography (MAMMOMAT), MRI, and AI imaging solutions for the same radiology departments and breast centers IzoView targets. Comparable as an established, multi-modality competitor with strong European footprint aligned to Izotropic's planned EU-first launch.
  • Philips Healthcare: Philips offers mammography, ultrasound, MRI, and AI-enabled diagnostic imaging for similar hospital and breast-center buyers. Comparable as a broad incumbent competing for the same capital equipment budget and radiology workflow share.
  • GE HealthCare: GE offers mammography (Senographe Pristina), MRI, and contrast-enhanced imaging across the same hospital buyers as Izotropic. It is a broad incumbent whose installed base and service network set the competitive benchmark for breast imaging procurement.

Emerging players

  • Lunit: Lunit develops AI software (Lunit INSIGHT) for mammography and DBT breast cancer detection, with FDA-cleared products. Comparable as a software-AI peer in breast imaging whose AI-vs-AI narrative parallels Izotropic's AI reconstruction and planned CADx positioning.
  • Volpara Health: Volpara provides breast density assessment and AI-based imaging analytics software integrated with mammography workflows. Comparable as an emerging software peer addressing the dense-breast population that IzoView's primary indication targets, although Volpara is software-only rather than capital equipment.
  • iCAD: iCAD provides AI-based computer-aided detection (ProFound AI) for breast cancer screening on mammography and DBT. Comparable because it overlaps with Izotropic's planned CADx module and targets the same radiologist end-user with AI decision support. Izotropic's former regulatory consultant John DeLucia was previously VP at iCAD.

Direct peers

  • Koning Health: Koning is the most directly comparable peer — a commercial-stage developer of dedicated cone-beam breast CT systems (Koning KBCT) that compete head-to-head with IzoView in the dedicated breast CT category. Both target the dense-breast screening indication and the same hospital/imaging-center buyer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Izotropic social profiles

Digital presence

Izotropic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Izotropic leadership team

Management profile

Number of profiles

Profiles13 records

Izotropic subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Izotropic funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Izotropic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Izotropic

What does Izotropic do?

Izotropic develops and intends to commercialize the IzoView Breast CT Imaging System, a dedicated breast computed tomography platform engineered for breast cancer screening in women with dense breast tissue. The device delivers true 3D, 360-degree volumetric breast imaging without compression, supported by a proprietary AI-based machine-learning reconstruction algorithm developed with Johns Hopkins University. The system is being positioned for adjunctive screening to digital breast tomosynthesis (DBT) at a target sales price of $500,000 per unit, with planned software-enabled expansion across 14 potential indications for use.

Is Izotropic a public or private company?

Izotropic is a public company. It is classified as public and is currently operating.

When was Izotropic founded?

Izotropic was founded in 2015. It employs 1 to 10 people.

Where is Izotropic based?

Izotropic is headquartered in Vancouver, Canada, in the North America region.

How does Izotropic make money?

Three revenue lines are on record. IzoView Breast CT Device Sales are the primary driver. The others are software Upgrades and Expanded Indications and sublicensing and Distribution Fees (Izotropic Africa).

Who are Izotropic's main competitors?

Broad incumbents on record are Hologic, Fujifilm Healthcare, Canon Medical Systems, Siemens Healthineers, Philips Healthcare and GE HealthCare. Emerging players are Lunit, Volpara Health and iCAD. Koning Health is listed as a direct peer.

Does Izotropic have an API?

No public API is recorded for Izotropic.

What industry is Izotropic in?

Izotropic's product category is Breast Imaging Diagnostic Equipment. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 339112 and its SIC code is 3844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsIzotropic Corporation (OTCMKTS:IZOZF) Shares Shorted: Short Interest Up 1,938.3% in SeptemberShort interest in Izotropic Corporation rose 1,938.3% to 17,142 shares as of September 30th. The company reported a quarterly loss of $0.01 per share, missing analysts' consensus of $0.01. Analysts expect a fiscal-year EPS of $0.03.Seeking AlphaIzotropic announces private placement of 750,000 units (IZOZF:OTCMKTS)Izotropic Corporation announced a non-brokered private placement of 750,000 units at $0.20 each, targeting gross proceeds of up to $150,000. The company intends to sell the units to a strategic investor.NewsfileIzotropic Announces Non-Brokered Private PlacementIzotropic Corporation announced a non-brokered private placement of 750,000 units at $0.20 each, raising up to $150,000. Proceeds will fund general working capital, and completion is subject to regulatory approvals. The securities are not registered under the U.S. Securities Act.AktienIzotropic Announces Non-Brokered Private PlacementIzotropic Corporation announced a non-brokered private placement of 750,000 units at $0.20 each, raising up to $150,000 gross proceeds. Proceeds will be used for general working capital, and completion is subject to regulatory approvals.BioSpaceIzotropic Announces Non-Brokered Private PlacementIzotropic Corporation announced a non-brokered private placement of 750,000 units at $0.20 each, raising up to $150,000 gross proceeds. Each unit includes a warrant to buy one share at $0.30 for three years. Proceeds will fund general working capital, subject to regulatory approvals.Ticker ReportIzotropic Corporation (OTCMKTS:IZOZF) Short Interest UpdateIzotropic Corporation's short interest fell 43.6% to 12,852 shares as of August 31st, from 22,790 on August 15th. The stock opened at $0.15, with a 50-day moving average of $0.17 and a two-hundred-day average of $0.18.YahooIZOZF Making StridesA research report on Izotropic Corporation (OTCQB: IZOZF, CSE: IZO) describes its IzoView breast CT imaging platform, which produces three-dimensional volumetric images without breast compression, contrasting with two-dimensional mammography. The report cites a global breast imaging market forecast of roughly $9 billion by the end of the decade and notes regulatory review remains ongoing.Markets DailyIzotropic Corporation (OTCMKTS:IZOZF) Short Interest UpdateIzotropic Corporation reported a 47.1% decline in short interest for July, with outstanding short positions dropping to 16,552 shares by the end of the month. The company's stock price rose 1.3% during Friday trading, closing at $0.17 with a volume of 4,500 shares. Izotropic is a Canadian research and development firm that develops diagnostic products, including the IzoView CT imaging device.YahooIZOZF Presents Opportunity for InvestorsIzotropic Corporation (OTCQB: IZOZF; CSE: IZO), a medical technology company, is being highlighted as an investment opportunity focused on its IzoView Breast CT imaging platform for breast cancer detection. The platform offers advantages over traditional mammography by providing three-dimensional volumetric images without breast compression, with plans to incorporate AI-assisted capabilities. Industry forecasts estimate the global breast imaging market could reach approximately $9 billion by the end of the decade, though regulatory review for IzoView remains ongoing.Stock TitanIzotropic signs Africa, GCC distribution pactIzotropic Corporation has executed a Formal Agreement with Izotropic Africa (IZAF), establishing a joint venture with 51% ownership held by IZAF shareholders and 49% by Izotropic, appointing IZAF as the exclusive distributor for IzoView, its dedicated breast CT imaging system, throughout Africa and the GCC for an initial five-year term. The agreement grants IZAF responsibility for sales, marketing, regulatory engagement, installation, and technical support, while Izotropic retains manufacturing, product development, and intellectual property ownership. IZAF plans to expand regulatory submissions across key jurisdictions, deploy initial clinical systems, and explore establishing a high-technology manufacturing facility in Morocco to position it as a regional hub.